Gilead Sciences Inc
NASDAQ:GILD

Watchlist Manager
Gilead Sciences Inc Logo
Gilead Sciences Inc
NASDAQ:GILD
Watchlist
Price: 116.04 USD 0.52% Market Closed
Market Cap: 144.6B USD
Have any thoughts about
Gilead Sciences Inc?
Write Note

Intrinsic Value

The intrinsic value of one GILD stock under the Base Case scenario is 102.99 USD. Compared to the current market price of 116.04 USD, Gilead Sciences Inc is Overvalued by 11%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

GILD Intrinsic Value
102.99 USD
Overvaluation 11%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Gilead Sciences Inc

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
GILD
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for GILD cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Gilead’s heavy reliance on its HIV portfolio could hinder long-term growth if new competitive therapies and emerging generics erode market share faster than forecast, putting pressure on revenues and margins.

Despite significant investments in oncology, some of Gilead’s pipeline candidates have faced setbacks, raising doubts about the company’s ability to diversify beyond its core antivirals and deliver strong returns on high-cost acquisitions.

Stagnating sales in the hepatitis C segment, amplified by intensified competition and price pressures, may challenge management’s efforts to sustain overall top-line growth and maintain investor confidence.

Bull Theses

Gilead’s robust HIV franchise, led by Biktarvy, continues to post solid growth and enjoy strong patent protection, providing a stable revenue base and healthy cash flow to fund R&D and strategic acquisitions.

The company’s expanding oncology pipeline, bolstered by acquisitions like Kite Pharma and Immunomedics, offers potential for long-term diversification as novel cell and targeted therapies begin to gain traction in large cancer markets.

Gilead’s consistent free cash flow generation affords management the flexibility to pursue strategic partnerships and invest aggressively in innovative therapeutic areas, positioning the firm ahead of rivals seeking to build similar franchises.

Show More Less
How do you feel about GILD?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Gilead Sciences Inc

Provide an overview of the primary business activities
of Gilead Sciences Inc.

What unique competitive advantages
does Gilead Sciences Inc hold over its rivals?

What risks and challenges
does Gilead Sciences Inc face in the near future?

Has there been any significant insider trading activity
in Gilead Sciences Inc recently?

Summarize the latest earnings call
of Gilead Sciences Inc.

What significant events have occurred
in Gilead Sciences Inc over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Gilead Sciences Inc.

Provide P/S
for Gilead Sciences Inc.

Provide P/E
for Gilead Sciences Inc.

Provide P/OCF
for Gilead Sciences Inc.

Provide P/FCFE
for Gilead Sciences Inc.

Provide P/B
for Gilead Sciences Inc.

Provide EV/S
for Gilead Sciences Inc.

Provide EV/GP
for Gilead Sciences Inc.

Provide EV/EBITDA
for Gilead Sciences Inc.

Provide EV/EBIT
for Gilead Sciences Inc.

Provide EV/OCF
for Gilead Sciences Inc.

Provide EV/FCFF
for Gilead Sciences Inc.

Provide EV/IC
for Gilead Sciences Inc.

Show me price targets
for Gilead Sciences Inc made by professional analysts.

What are the Revenue projections
for Gilead Sciences Inc?

How accurate were the past Revenue estimates
for Gilead Sciences Inc?

What are the Net Income projections
for Gilead Sciences Inc?

How accurate were the past Net Income estimates
for Gilead Sciences Inc?

What are the EPS projections
for Gilead Sciences Inc?

How accurate were the past EPS estimates
for Gilead Sciences Inc?

What are the EBIT projections
for Gilead Sciences Inc?

How accurate were the past EBIT estimates
for Gilead Sciences Inc?

Compare the revenue forecasts
for Gilead Sciences Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Gilead Sciences Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Gilead Sciences Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Gilead Sciences Inc compared to its peers.

Compare the P/E ratios
of Gilead Sciences Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Gilead Sciences Inc with its peers.

Analyze the financial leverage
of Gilead Sciences Inc compared to its main competitors.

Show all profitability ratios
for Gilead Sciences Inc.

Provide ROE
for Gilead Sciences Inc.

Provide ROA
for Gilead Sciences Inc.

Provide ROIC
for Gilead Sciences Inc.

Provide ROCE
for Gilead Sciences Inc.

Provide Gross Margin
for Gilead Sciences Inc.

Provide Operating Margin
for Gilead Sciences Inc.

Provide Net Margin
for Gilead Sciences Inc.

Provide FCF Margin
for Gilead Sciences Inc.

Show all solvency ratios
for Gilead Sciences Inc.

Provide D/E Ratio
for Gilead Sciences Inc.

Provide D/A Ratio
for Gilead Sciences Inc.

Provide Interest Coverage Ratio
for Gilead Sciences Inc.

Provide Altman Z-Score Ratio
for Gilead Sciences Inc.

Provide Quick Ratio
for Gilead Sciences Inc.

Provide Current Ratio
for Gilead Sciences Inc.

Provide Cash Ratio
for Gilead Sciences Inc.

What is the historical Revenue growth
over the last 5 years for Gilead Sciences Inc?

What is the historical Net Income growth
over the last 5 years for Gilead Sciences Inc?

What is the current Free Cash Flow
of Gilead Sciences Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Gilead Sciences Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Gilead Sciences Inc

Current Assets 18B
Cash & Short-Term Investments 10B
Receivables 4.4B
Other Current Assets 3.6B
Non-Current Assets 41B
PP&E 5.4B
Intangibles 28.3B
Other Non-Current Assets 7.3B
Current Liabilities 12B
Other Current Liabilities 12B
Non-Current Liabilities 27.7B
Other Non-Current Liabilities 27.7B
Efficiency

Free Cash Flow Analysis
Gilead Sciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Gilead Sciences Inc

Revenue
28.8B USD
Cost of Revenue
-6.3B USD
Gross Profit
22.5B USD
Operating Expenses
-11.6B USD
Operating Income
10.9B USD
Other Expenses
-10.4B USD
Net Income
480m USD
Fundamental Scores

GILD Profitability Score
Profitability Due Diligence

Gilead Sciences Inc's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

Positive Free Cash Flow
Positive Gross Profit
Positive Operating Income
Positive 3-Year Average ROE
62/100
Profitability
Score

Gilead Sciences Inc's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

GILD Solvency Score
Solvency Due Diligence

Gilead Sciences Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Average Altman Z-Score
60/100
Solvency
Score

Gilead Sciences Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GILD Price Targets Summary
Gilead Sciences Inc

Wall Street analysts forecast GILD stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GILD is 109.81 USD with a low forecast of 82.82 USD and a high forecast of 136.5 USD.

Lowest
Price Target
82.82 USD
29% Downside
Average
Price Target
109.81 USD
5% Downside
Highest
Price Target
136.5 USD
18% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Previous Payment
-
Today
Next Payment
-
Today
Mar 7, 2025
Previous Payment
-
Next Payment
-
Ex-Dividend Date
-
Shareholder Yield

Current shareholder yield for GILD is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

GILD Insider Trading
Buy and sell transactions by insiders

GILD News

Other Videos
What is the Intrinsic Value of one GILD stock?

The intrinsic value of one GILD stock under the Base Case scenario is 102.99 USD.

Is GILD stock undervalued or overvalued?

Compared to the current market price of 116.04 USD, Gilead Sciences Inc is Overvalued by 11%.

Back to Top